154 related articles for article (PubMed ID: 28980709)
1. Current strategies for the management of autologous peripheral blood stem cell mobilization failures in patients with multiple myeloma.
Sahin U; Demirer T
J Clin Apher; 2018 Jun; 33(3):357-370. PubMed ID: 28980709
[TBL] [Abstract][Full Text] [Related]
2. Poor peripheral blood stem cell mobilization affects long-term outcomes in multiple myeloma patients undergoing autologous stem cell transplantation.
Moreb JS; Byrne M; Shugarman I; Zou F; Xiong S; May WS; Norkin M; Hiemenz J; Brown R; Cogle C; Wingard JR; Hsu JW
J Clin Apher; 2018 Feb; 33(1):29-37. PubMed ID: 28556233
[TBL] [Abstract][Full Text] [Related]
3. Advanced lytic lesion is a poor mobilization factor in peripheral blood stem cell collection in patients with multiple myeloma.
Jung SH; Yang DH; Ahn JS; Kim YK; Kim HJ; Lee JJ
J Clin Apher; 2014 Dec; 29(6):305-10. PubMed ID: 24764270
[TBL] [Abstract][Full Text] [Related]
4. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F
Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715
[TBL] [Abstract][Full Text] [Related]
5. Predicting hematopoietic stem cell mobilization failure in patients with multiple myeloma: a simple method using day 1 CD34+ cell yield.
Duong HK; Bolwell BJ; Rybicki L; Koo A; Hsi ED; Figueroa P; Dean R; Pohlman B; Kalaycio M; Andresen S; Sobecks R; Copelan E
J Clin Apher; 2011; 26(3):111-5. PubMed ID: 21647951
[TBL] [Abstract][Full Text] [Related]
6. Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single-center experience.
He X; Jiang D; Zhao L; Chen S; Zhu Y; He Q; He Y
Cancer Med; 2024 Jun; 13(11):e7356. PubMed ID: 38850125
[TBL] [Abstract][Full Text] [Related]
7. A single dose of 6 or 12 mg of pegfilgrastim for peripheral blood progenitor cell mobilization results in similar yields of CD34+ progenitors in patients with multiple myeloma.
Bruns I; Steidl U; Kronenwett R; Fenk R; Graef T; Rohr UP; Neumann F; Fischer J; Scheid C; Hübel K; Haas R; Kobbe G
Transfusion; 2006 Feb; 46(2):180-5. PubMed ID: 16441592
[TBL] [Abstract][Full Text] [Related]
8. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
9. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
10. [Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma].
Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gribanova EO; Alekseeva IV; Drokov MIu; Kalinin NN; Gretsov EM; Kliasova GA; Savchenko VG
Ter Arkh; 2011; 83(7):50-7. PubMed ID: 21894752
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma.
Demirer T; Buckner CD; Gooley T; Appelbaum FR; Rowley S; Chauncey T; Lilleby K; Storb R; Bensinger WI
Bone Marrow Transplant; 1996 Jun; 17(6):937-41. PubMed ID: 8807097
[TBL] [Abstract][Full Text] [Related]
12. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation.
Wuchter P; Ran D; Bruckner T; Schmitt T; Witzens-Harig M; Neben K; Goldschmidt H; Ho AD
Biol Blood Marrow Transplant; 2010 Apr; 16(4):490-9. PubMed ID: 19925876
[TBL] [Abstract][Full Text] [Related]
13. Stem cell mobilization and autologous stem cell transplantation after pretreatment with bendamustine, prednisone and bortezomib (BPV) in newly diagnosed multiple myeloma.
Poenisch W; Plötze M; Holzvogt B; Andrea M; Schliwa T; Zehrfeld T; Hammerschmidt D; Schwarz M; Edelmann T; Becker C; Hoffmann FA; Schwarzer A; Kreibich U; Gutsche K; Reifenrath K; Schwarzbach H; Heyn S; Franke GN; Jentzsch M; Leiblein S; Schwind S; Lange T; Vucinic V; AlAli HK; Niederwieser D
J Cancer Res Clin Oncol; 2015 Nov; 141(11):2013-22. PubMed ID: 25976868
[TBL] [Abstract][Full Text] [Related]
14. Predictive factors for poor peripheral blood stem cell mobilization and peak CD34(+) cell count to guide pre-emptive or immediate rescue mobilization.
Sancho JM; Morgades M; Grifols JR; Juncà J; Guardia R; Vives S; Ferrà C; Batlle M; Ester A; Gallardo D; Millà F; Feliu E; Ribera JM
Cytotherapy; 2012 Aug; 14(7):823-9. PubMed ID: 22540329
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood hematopoietic stem cell mobilization and collection efficacy is not an independent prognostic factor for autologous stem cell transplantation.
Wang S; Nademanee A; Qian D; Dagis A; Park HS; Fridey J; Smith E; Snyder D; Somlo G; Stein A; Rosenthal J; Falk P; Kogut N; Palmer J; Gaal K; Kim Y; Bhatia R; Yuan S; Kay C; Weiss L; Forman S
Transfusion; 2007 Dec; 47(12):2207-16. PubMed ID: 17714420
[TBL] [Abstract][Full Text] [Related]
16. Improved Prediction of CD34+ Cell Yield before Peripheral Blood Hematopoietic Progenitor Cell Collection Using a Modified Target Value-Tailored Approach.
Sheppard D; Tay J; Palmer D; Xenocostas A; Doulaverakis C; Huebsch L; McDiarmid S; Tinmouth A; Mallick R; Martin L; Birch P; Hamelin L; Allan D; Bredeson C
Biol Blood Marrow Transplant; 2016 Apr; 22(4):763-767. PubMed ID: 26643030
[TBL] [Abstract][Full Text] [Related]
17. Cyclophosphamide-based stem cell mobilization in relapsed multiple myeloma patients: A subgroup analysis from the phase III trial ReLApsE.
Baertsch MA; Schlenzka J; Lisenko K; Krzykalla J; Becker N; Weisel K; Noppeney R; Martin H; Lindemann HW; Haenel M; Nogai A; Scheid C; Salwender H; Fenk R; Graeven U; Reimer P; Schmidt-Hieber M; Goerner M; Schmidt-Wolf IGH; Klein S; Ho AD; Goldschmidt H; Wuchter P
Eur J Haematol; 2017 Jul; 99(1):42-50. PubMed ID: 28370401
[TBL] [Abstract][Full Text] [Related]
18. The comparison of Filgrastim (Neupogen®), biosimilar filgrastim (Leucostim®) and Lenograstim (Granocyte®) as a first line peripheral blood stem cell mobilization strategy in autologous hematopoieitic stem cell transplantation: a single center experience from Turkey.
Sivgin S; Karakus E; Kaynar L; Kurnaz F; Pala C; Keklik M; Zararsiz G; Solmaz M; Eser B; Cetin M; Unal A
Transfus Apher Sci; 2013 Jun; 48(3):315-20. PubMed ID: 23611684
[TBL] [Abstract][Full Text] [Related]
19. Filgrastim-alone versus pegylated filgrastim-alone for autologous peripheral blood stem cells mobilization in newly diagnosed multiple myeloma patients.
Skopec B; Skerget M; Zontar D; Zadnik V; Zver S
Wien Klin Wochenschr; 2017 Aug; 129(15-16):545-551. PubMed ID: 28439700
[TBL] [Abstract][Full Text] [Related]
20. Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patients.
Kolbe K; Peschel C; Rupilius B; Després D; Burger K; Sklenar I; Färber L; Huber C; Derigs HG
Bone Marrow Transplant; 1997 Dec; 20(12):1027-32. PubMed ID: 9466274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
